- Home
- DDI vs DMAC Comparison
DDI vs DMAC Comparison
Compare DDI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDI
- DMAC
- Stock Information
- Founded
- DDI 2008
- DMAC 2000
- Country
- DDI South Korea
- DMAC United States
- Employees
- DDI N/A
- DMAC N/A
- Industry
- DDI EDP Services
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- DDI Technology
- DMAC Health Care
- Exchange
- DDI Nasdaq
- DMAC Nasdaq
- Market Cap
- DDI 489.1M
- DMAC 178.0M
- IPO Year
- DDI 2021
- DMAC N/A
- Fundamental
- Price
- DDI $9.60
- DMAC $3.57
- Analyst Decision
- DDI Strong Buy
- DMAC Strong Buy
- Analyst Count
- DDI 5
- DMAC 2
- Target Price
- DDI $19.60
- DMAC $8.00
- AVG Volume (30 Days)
- DDI 133.5K
- DMAC 307.0K
- Earning Date
- DDI 08-11-2025
- DMAC 08-06-2025
- Dividend Yield
- DDI N/A
- DMAC N/A
- EPS Growth
- DDI 9.79
- DMAC N/A
- EPS
- DDI 2.37
- DMAC N/A
- Revenue
- DDI $336,679,000.00
- DMAC N/A
- Revenue This Year
- DDI $8.25
- DMAC N/A
- Revenue Next Year
- DDI $3.39
- DMAC N/A
- P/E Ratio
- DDI $4.02
- DMAC N/A
- Revenue Growth
- DDI 5.41
- DMAC N/A
- 52 Week Low
- DDI $8.09
- DMAC $2.72
- 52 Week High
- DDI $18.21
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- DDI 49.94
- DMAC 40.50
- Support Level
- DDI $9.37
- DMAC $3.70
- Resistance Level
- DDI $9.84
- DMAC $3.99
- Average True Range (ATR)
- DDI 0.44
- DMAC 0.31
- MACD
- DDI 0.05
- DMAC -0.01
- Stochastic Oscillator
- DDI 86.29
- DMAC 13.67
About DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. Its market opportunity includes casual gaming globally, which includes slots, puzzles, cards, match three, and other similar games. Within the social casino segment of casual gaming, which includes free-to-play online slots, poker, table games, and bingo. Other games developed by the company are DoubleDown Fort, DoubleDown Classic, and Ellen's Road to Riches. The company has a presence in the international market, and it derives a majority of its revenue from the United States of America.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.